| |
Characteristic
|
Total
|
Survivors
|
Non-survivors
|
p-value
|
|---|
|
Gender
|
Male
|
17
|
12
|
5
|
0.29
|
|
Female
|
5
|
5
|
0
| |
|
Race
|
White or Caucasian
|
17
|
13
|
4
|
1
|
|
Black or African American
|
2
|
2
|
0
| |
|
Other
|
3
|
2
|
1
| |
|
Age
|
Median (IQR)
|
62.5 (42–66.5)
|
61 (38.5–65)
|
65 (62.5–76)
|
0.085
|
|
Etiology
|
Ischemic
|
6
|
2
|
4
|
0.009
|
|
Non-Ischemic
|
16
|
15
|
1
| |
|
Diabetes
|
Diabetic
|
7
|
6
|
1
|
1
|
|
Non-Diabetic
|
15
|
11
|
4
| |
|
INTERMACS
|
1 (Critical cardiogenic shock)
|
2
|
1
|
1
|
0.23
|
|
2 (Progressive decline)
|
12
|
10
|
2
| |
|
3 (Stable, but inotrope dependent)
|
7
|
6
|
1
| |
|
4 (Resting symptoms)
|
1
|
0
|
1
| |
|
MCS Device
|
HeartMate II
|
13
|
11
|
2
|
0.25
|
|
HeartWare
|
1
|
1
|
0
| |
|
HeartMate II, CentriMag
|
4
|
2
|
2
| |
|
TAH
|
1
|
1
|
0
| |
|
PVAD
|
2
|
2
|
0
| |
|
CentriMag BVAD
|
1
|
0
|
1
| |
